Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This drug is a topical combination therapy developed by Hubei Kangzheng Pharmaceutical, containing triamcinolone acetonide, miconazole nitrate, and neomycin sulfate. It is specifically formulated for the treatment of mixed bacterial and fungal skin infections that are accompanied by significant inflammation. Triamcinolone acetonide is a potent synthetic corticosteroid that provides anti-inflammatory, antipruritic, and vasoconstrictive effects by activating glucocorticoid receptors. Miconazole is an imidazole antifungal agent that works by inhibiting the synthesis of ergosterol, thereby disrupting fungal cell membrane integrity. Neomycin is an aminoglycoside antibiotic that targets bacterial protein synthesis by binding to the 30S ribosomal subunit. This triple-action approach allows for the simultaneous management of infection and the symptomatic relief of associated skin irritation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on triamcinolone acetonide + miconazole + neomycin.